Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Axsome Therapeutics (AXSM) Leases (2022 - 2025)

Axsome Therapeutics' Leases history spans 4 years, with the latest figure at $20.9 million for Q4 2025.

  • For Q4 2025, Leases rose 287.48% year-over-year to $20.9 million; the TTM value through Dec 2025 reached $20.9 million, up 287.48%, while the annual FY2025 figure was $20.9 million, 287.48% up from the prior year.
  • Leases for Q4 2025 was $20.9 million at Axsome Therapeutics, down from $21.7 million in the prior quarter.
  • Across five years, Leases topped out at $23.9 million in Q1 2025 and bottomed at $106000.0 in Q1 2023.
  • The 4-year median for Leases is $6.2 million (2024), against an average of $8.5 million.
  • The largest annual shift saw Leases crashed 88.8% in 2023 before it surged 5948.11% in 2024.
  • A 4-year view of Leases shows it stood at $420000.0 in 2022, then skyrocketed by 1512.38% to $6.8 million in 2023, then decreased by 20.51% to $5.4 million in 2024, then skyrocketed by 287.48% to $20.9 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Leases are $20.9 million (Q4 2025), $21.7 million (Q3 2025), and $22.5 million (Q2 2025).